BR112012000421A2 - composições e métodos para intensificar a produção de um produto biológico. - Google Patents

composições e métodos para intensificar a produção de um produto biológico.

Info

Publication number
BR112012000421A2
BR112012000421A2 BR112012000421A BR112012000421A BR112012000421A2 BR 112012000421 A2 BR112012000421 A2 BR 112012000421A2 BR 112012000421 A BR112012000421 A BR 112012000421A BR 112012000421 A BR112012000421 A BR 112012000421A BR 112012000421 A2 BR112012000421 A2 BR 112012000421A2
Authority
BR
Brazil
Prior art keywords
enhancing
compositions
production
methods
biological product
Prior art date
Application number
BR112012000421A
Other languages
English (en)
Inventor
Rossomando Anthony
Bettencourt Brian
Kocisko David
Hinkle Greg
M Maraganore John
Manoharan Muthian
Hogan Shannon
Pollard Stuart
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of BR112012000421A2 publication Critical patent/BR112012000421A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112012000421A 2009-07-06 2010-07-06 composições e métodos para intensificar a produção de um produto biológico. BR112012000421A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US22337009P 2009-07-06 2009-07-06
US24486809P 2009-09-22 2009-09-22
US26741909P 2009-12-07 2009-12-07
US29398010P 2010-01-11 2010-01-11
US31958910P 2010-03-31 2010-03-31
US33439810P 2010-05-13 2010-05-13
US35493210P 2010-06-15 2010-06-15
PCT/US2010/041099 WO2011005786A2 (en) 2009-07-06 2010-07-06 Compositions and methods for enhancing production of a biological product

Publications (1)

Publication Number Publication Date
BR112012000421A2 true BR112012000421A2 (pt) 2019-09-24

Family

ID=43429810

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000421A BR112012000421A2 (pt) 2009-07-06 2010-07-06 composições e métodos para intensificar a produção de um produto biológico.

Country Status (6)

Country Link
US (1) US20140099666A1 (pt)
EP (1) EP2451823A4 (pt)
JP (1) JP2014501097A (pt)
BR (1) BR112012000421A2 (pt)
CA (1) CA2767225A1 (pt)
WO (1) WO2011005786A2 (pt)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
WO2011071860A2 (en) * 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
AU2014280918B2 (en) * 2009-12-18 2016-11-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat HSF1-related diseases
KR101605932B1 (ko) 2009-12-18 2016-03-24 노파르티스 아게 Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물
US20120191434A1 (en) * 2010-08-25 2012-07-26 Gt Life Sciences, Inc. Articles of manufacture and methods for modeling chinese hamster ovary (cho) cell metabolism
WO2012177639A2 (en) * 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
EP2773777B1 (en) 2011-10-31 2020-05-13 University of Utah Research Foundation Genetic alterations in glioblastoma
WO2013102155A1 (en) * 2011-12-29 2013-07-04 Cell Machines, Inc. Cells for virus and protein production
WO2013148283A1 (en) 2012-03-30 2013-10-03 Isis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
KR20150030205A (ko) 2012-05-16 2015-03-19 라나 테라퓨틱스, 인크. Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
ES2921623T3 (es) * 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
JP2016504050A (ja) 2013-01-17 2016-02-12 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
CN111254145A (zh) 2013-03-14 2020-06-09 Ionis制药公司 用于调节tau表达的组合物和方法
CA2921162A1 (en) 2013-05-01 2014-11-06 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
TWI657819B (zh) 2013-07-19 2019-05-01 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
EP2865758A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
BR112016020287B1 (pt) * 2014-03-04 2022-06-28 Sigma-Aldrich Co. Llc Uso de uma linhagem celular de ovário de hamster chinês (cho) geneticamente modificada, composição e métodos para reduzir o risco de contaminação viral de um sistema de produção biológico e para reduzir ou prevenir a contaminação viral de um produto de proteína recombinante
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN112410338A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
US20190038659A1 (en) 2015-09-29 2019-02-07 The Usa, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing amyotrophic lateral sclerosis
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017066657A1 (en) * 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Nucleic acid based tia-1 inhibitors
EP3368054A4 (en) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
KR20220108216A (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
US11710048B2 (en) 2016-07-05 2023-07-25 Samsung Electronics Co., Ltd. Method and device for assessing feasibility of biochemical reaction in organism
CN110650673B (zh) 2016-08-30 2024-04-09 加利福尼亚大学董事会 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
ES2963428T3 (es) 2016-09-29 2024-03-27 Biogen Ma Inc Compuestos y métodos para reducir la expresión de Tau
KR101837855B1 (ko) 2016-10-18 2018-03-13 단국대학교 산학협력단 뎅기바이러스 혈청형 2의 메틸트랜스퍼라제 활성을 억제하는 rna 앱타머
CN109952370B (zh) * 2016-10-19 2023-09-08 豪夫迈·罗氏有限公司 用于产生免疫缀合物的方法
SG11201909870SA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
CN118236391A (zh) 2017-12-01 2024-06-25 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN110997919B (zh) 2017-12-01 2024-04-02 苏州瑞博生物技术股份有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
JP7261494B2 (ja) 2017-12-01 2023-04-20 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
US11660347B2 (en) 2017-12-01 2023-05-30 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
WO2019105435A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019115417A2 (en) * 2017-12-12 2019-06-20 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating rb1 expression
CN110959011B (zh) 2017-12-29 2023-03-28 苏州瑞博生物技术股份有限公司 缀合物及其制备方法和用途
US20210010028A1 (en) 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
MD3762368T2 (ro) 2018-03-08 2022-07-31 Incyte Corp Compuși diol aminopirazină ca inhibitori ai PI3K-Y
EP4242307A3 (en) * 2018-04-12 2023-12-27 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
EP3793615A2 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Directed evolution of aav to improve tropism for cns
EP3793686A1 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
WO2020007702A1 (en) * 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting bcl2l11
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CA3103963A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
JP2021530548A (ja) 2018-07-24 2021-11-11 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. 遺伝子治療製剤を生産するための系および方法
EP3842534A4 (en) 2018-08-21 2022-07-06 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE WITH NUCLEIC ACID AND THEIR USE
EP3628735A1 (en) * 2018-09-25 2020-04-01 Centre National De La Recherche Scientifique Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease
CN113383010B (zh) 2018-09-28 2025-09-09 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
EP3862024A4 (en) 2018-09-30 2022-08-17 Suzhou Ribo Life Science Co., Ltd. SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
WO2020077165A1 (en) 2018-10-12 2020-04-16 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
GB201817971D0 (en) 2018-11-02 2018-12-19 British American Tobacco Investments Ltd Method
CN113423729A (zh) * 2018-11-06 2021-09-21 迈阿密大学 能够在体内进行糖工程化的重组aav病毒载体的组合物和产生
CN112423794A (zh) 2018-12-28 2021-02-26 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
MX2021008542A (es) 2019-01-18 2021-11-12 Voyager Therapeutics Inc Métodos y sistemas para la producción de partículas de aav.
CN109852648B (zh) * 2019-04-11 2022-08-09 广西大学 酶法制备右旋糖酐硒聚物的方法
WO2020223274A1 (en) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
CN110117607A (zh) * 2019-04-29 2019-08-13 贵州大学 一种玉米黑粉菌效应蛋白Pit2基因的重组载体和表达方法
AU2020269323A1 (en) * 2019-05-07 2021-10-28 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of PROS1 in a cell
US11162102B2 (en) 2019-05-13 2021-11-02 Dna Twopointo Inc. Modifications of mammalian cells using artificial micro-RNA to alter their properties and the compositions of their products
JP7663951B2 (ja) 2019-05-22 2025-04-17 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
CN113811613B (zh) 2019-05-22 2024-04-05 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
AU2020280439B2 (en) 2019-05-22 2025-08-14 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
WO2020238766A1 (zh) 2019-05-24 2020-12-03 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
US20220290182A1 (en) 2019-08-09 2022-09-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2021041485A1 (en) 2019-08-26 2021-03-04 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US12534688B2 (en) * 2019-10-07 2026-01-27 Conopco, Inc. Fabric softener composition comprising a betaine ester and a fatty co-softener
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
WO2022032282A1 (en) * 2020-08-06 2022-02-10 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Methods and reagents for microbiome analysis
WO2022032153A1 (en) 2020-08-06 2022-02-10 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
IL290590A (en) * 2020-08-14 2022-04-01 Univ Massachusetts Cell culture methods
US20230313187A1 (en) * 2020-09-04 2023-10-05 Dna Twopointo Inc. Modifications of mammalian cells using artificial micro-rna to alter their properties and the compositions of their products
IT202000023647A1 (it) * 2020-10-07 2022-04-07 Univ Degli Studi Padova Sirna nel trattamento della sindrome ectrodattilia-displasia ectodermica-palatoschisi (eec)
CN112430625B (zh) * 2020-11-23 2022-08-05 武汉枢密脑科学技术有限公司 含有变异猪伪狂犬病病毒gD蛋白基因的重组腺相关病毒转移载体、病毒及其制备和应用
EP4301768A2 (en) 2021-03-03 2024-01-10 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
JP2024514222A (ja) * 2021-04-19 2024-03-28 ジェネンテック， インコーポレイテッド 改変された哺乳動物細胞
CN117794570A (zh) * 2021-06-02 2024-03-29 西韦克生物技术有限责任公司 抗体、抗体衍生物和多肽向真核细胞的细菌递送
AU2022298641A1 (en) * 2021-06-22 2024-02-01 University Of Massachusetts OLIGONUCLEOTIDES FOR IFN-γ SIGNALING PATHWAY MODULATION
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
EP4448762A1 (en) * 2021-12-17 2024-10-23 F. Hoffmann-La Roche AG Oligonucleotides capable of increasing glucocerebrosidase expression
CN114317511B (zh) * 2022-03-10 2022-06-14 北京爱普益医学检验中心有限公司 蛋白、基因、重组载体、表达盒、宿主及用途
CA3247176A1 (en) * 2022-04-08 2023-10-12 Secarna Pharmaceuticals Gmbh & Co. Kg OLIGONUCLEOTIDE TO REDUCE THE EXPRESSION OF LEUCINE-RICH REPEATED KINASE 2 (LRRK2) AND ITS USE TO PREVENT AND/OR TREAT HUMAN DISEASES
GB202208022D0 (en) * 2022-05-31 2022-07-13 Sisaf Ltd Therapeutic compounds and compositions
CN116064398A (zh) * 2022-07-04 2023-05-05 上海倍谙基生物科技有限公司 定点同步敲入和敲除基因的抗凋亡细胞改造方法及其应用
US20260085328A1 (en) 2022-09-08 2026-03-26 Voyager Therapeutics, Inc. Controlled expression of viral proteins
AU2023417630A1 (en) 2022-12-29 2025-05-15 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
WO2024165571A2 (en) * 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN116218762B (zh) * 2023-03-13 2025-08-29 深圳市中医院 肾小管类器官培养基及应用、肾小管类器官的培养方法
EP4735602A2 (en) 2023-06-27 2026-05-06 Atrium Therapeutics, Inc. Compositions and methods of using prkag2-targeting antibody-oligonucleotide conjugates abstract
CN116855497B (zh) * 2023-07-10 2025-09-12 暨南大学 一种抑制人USP46基因表达的siRNA和脂质体及其应用
CN117344061B (zh) * 2023-12-05 2024-02-27 云南省细胞质量检测评价中心有限公司 一种同时检测五种人源病毒ebv、hbv、hcv、hiv、hpv的方法、试剂盒、引物和探针及其应用
WO2025125576A2 (en) * 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) * 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025235441A1 (en) * 2024-05-08 2025-11-13 Vanderbilt University Overexpressing nsun2 to generate super producer cell line

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517644B1 (en) * 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
AU2002258477A1 (en) * 2001-03-08 2002-09-24 Advanced Cell Technology, Inc. Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture
KR100434118B1 (ko) * 2001-09-17 2004-06-04 한국과학기술원 카스파제-3에 대한 안티센스 뉴클레오타이드, 그의발현벡터 및 이를 이용한 세포예정사의 억제방법
US20090023670A1 (en) * 2006-05-19 2009-01-22 Sebestyen Magdolna G Regulation of Transgene Expression by RNA Interference
CA2663536A1 (en) * 2006-10-24 2008-05-02 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
WO2009012173A2 (en) * 2007-07-13 2009-01-22 Dharmacon, Inc. Enhanced biotherapeutic production using inhibitory rna

Also Published As

Publication number Publication date
WO2011005786A3 (en) 2011-03-24
JP2014501097A (ja) 2014-01-20
EP2451823A4 (en) 2013-07-03
US20140099666A1 (en) 2014-04-10
WO2011005786A2 (en) 2011-01-13
CA2767225A1 (en) 2011-01-13
EP2451823A2 (en) 2012-05-16

Similar Documents

Publication Publication Date Title
BRPI1013426A2 (pt) organismos para produção de 1,3-butanodiol
BRPI1010581A2 (pt) micro-organismos para a produção de 1,4-butanodiol e métodos relacionados
BRPI1012525A2 (pt) composições de nanopatículas isentas de príons e métodos para sua fabricação
HUE058971T2 (hu) RSV F fehérjekészítmények és eljárások azok elõállítására
BRPI1013822A2 (pt) Método para síntese de um trissacarídeo.
BR112012003365A2 (pt) método e dispositivo para a fabricação de objetos de titânio.
BRPI0908130A2 (pt) Produto
BRPI0925037A2 (pt) Composição contendo piceatanol e método de produzir a composição contendo piceatanol.
BRPI1012875A2 (pt) composições farmacêuticas sólidas e processos para sua produção
IT1393352B1 (it) Apparato di aliquotazione di contenitori di materiale biologico.
BRPI0913232A2 (pt) Produto alimentício
GB0904214D0 (en) Biological products
BRPI1011338A2 (pt) material de produção de embalagem
FI20085767L (fi) Kipsituote
BRPI1014090A2 (pt) produto de bebida instantânea
FI20095500A0 (fi) Tuote ja menetelmä sen valmistamiseksi
BRPI1010735A2 (pt) composição para a produção de um fungicida e um bactericida biológico
BR112012001731A2 (pt) Processo para a preparação de 1-benzil-3-hidroximetil-1h-indazol
GB0900425D0 (en) Biological products
BR112012025490A2 (pt) ''método para produção de 1,5 oebtanodiamina''
PT2509443E (pt) Produto alimentar gelificado
FR2944023B1 (fr) Procede de preparation de superplastifiants.
BRPI1010724A2 (pt) processo para produzir instrumentos médicos.
ITTO20110857A1 (it) Procedimento per la produzione di cicloesanonossina.
FI20086024A0 (fi) Uusi farmaseuttinen tuote

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.